Epipen has become big talk over recent controversy that the recent uptake in price has become more exponential than becoming eligible for the consumers to afford. Overall life expectancy and health status in the United States are improving; infant mortality is declining; and disability rates among the elderly have been falling nearly three times as fast as they did over the previous eight decades. This good news is bolstered by outsize increases in life expectancy and health status for Americans with heart disease, cancer, acquired immunodeficiency syndrome (AIDS), and preterm birth. These improvements in key components of our public’s health all point to one source: major pharmaceutical breakthroughs in the 1990s. Despite the managed care
…show more content…
Patients are “paying higher out of pocket costs,” she said. “The system wasn’t intended to have people pay the full wholesale acquisition cost, and that’s what’s happening at an alarming rate.” And simply lowering that wholesale acquisition cost wouldn’t assure that the savings would be passed on to consumers by insurers, drug benefit managers, and other players in the convoluted American health care industry.” Bresch stated, during a hearing on the increase of the price of Epipen. To put this into perspective the pharmaceutical company sends the drug to a distributor, which takes a fee and then sells the drug to a pharmacy, which pockets its own fee before dispensing the medication to a patient. If a patient is insured, a pharmacy-benefit manager is paid for processing the transaction between the pharmacy and the insurer or employer. The pharmacy-benefit manager also handles the rebates that flow from the drug maker to the insurer or the employer. Insurers and others say that lower figure obscures the larger price increases in specific areas like cancer treatment, where less competition exists and it is more difficult to pit manufacturers against one another. And drug makers do profit from raising their list prices because rebates and discounts are often based on a percentage of those prices. Do to the effecting markets of the pharmaceutical company, the real
Patients are “paying higher out of pocket costs,” she said. “The system wasn’t intended to have people pay the full wholesale acquisition cost, and that’s what’s happening at an alarming rate.” And simply lowering that wholesale acquisition cost wouldn’t assure that the savings would be passed on to consumers by insurers, drug benefit managers, and other players in the convoluted American health care industry.” Bresch stated, during a hearing on the increase of the price of Epipen. To put this into perspective the pharmaceutical company sends the drug to a distributor, which takes a fee and then sells the drug to a pharmacy, which pockets its own fee before dispensing the medication to a patient. If a patient is insured, a pharmacy-benefit manager is paid for processing the transaction between the pharmacy and the insurer or employer. The pharmacy-benefit manager also handles the rebates that flow from the drug maker to the insurer or the employer. Insurers and others say that lower figure obscures the larger price increases in specific areas like cancer treatment, where less competition exists and it is more difficult to pit manufacturers against one another. And drug makers do profit from raising their list prices because rebates and discounts are often based on a percentage of those prices. Do to the effecting markets of the pharmaceutical company, the real